Insys Therapeutics (INSY) Confirms FDA Panel on Buprenorphine Voted Not to Recommend Approval

May 22, 2018 3:09 PM
INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, confirmed ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles